Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience.
Shinya TsuboiTatsuya HayamaKatsuhiro MiuraAkihiro UchiikeDaisuke TsutsumiTakashi YamauchiYoshihiro HattaSusumu OotsukaPublished in: Journal of pharmaceutical health care and sciences (2023)
Younger age (< 55 years) was significantly associated with a higher risk of PIBP among patients receiving chemotherapy with a ≥ 10% risk of FN. Therefore, oncologists should meticulously formulate management plan for PIBP in younger patients after administering pegfilgrastim.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- locally advanced
- chemotherapy induced
- chronic pain
- prognostic factors
- neuropathic pain
- bone mineral density
- high glucose
- diabetic rats
- squamous cell carcinoma
- radiation therapy
- spinal cord injury
- spinal cord
- rectal cancer
- drug induced
- palliative care
- patient reported
- body composition
- endothelial cells
- oxidative stress